Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miroprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 4/20 | 0.76 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 7/20 | 0.61 |
| ▸ | PKM | P14618 | 4/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | CDC42 | P60953 | 1/20 | 0.58 |
| ▸ | RAC1 | P63000 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miroprofen SCHEMBL26767 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1KDM4ENPC1RAB9A | |
| Miroprofen SCHEMBL11832509 | 0.86 | PTGS2 (0.97) | PTGS2PTGS1KDM4ENPC1RAB9A | |
| SCHEMBL11130858 | 0.84 | PTGS2 (0.65) | PTGS2PTGS1KDM4ENPC1RAB9A | |
| SCHEMBL12608963 | 0.80 | PTGS1 (0.85) | PTGS2PTGS1KDM4ENPC1RAB9A | |
| SCHEMBL11825549 | 0.79 | PTGS1 (0.65) | PTGS2PTGS1KDM4ENPC1RAB9A | |
| Naproxen SCHEMBL28881206 | 0.79 | AKR1C3 (0.88) | PTGS2PTGS1AKR1C3AKR1C2TSHR | |
| SCHEMBL9293443 | 0.78 | NPC1 (1.00) | KDM4ENPC1RAB9APKMEPHX2 | |
| Naproxen SCHEMBL8092333 | 0.78 | AKR1C3 (0.97) | PTGS2PTGS1AKR1C3AKR1C2TSHR | |
| Naproxen SCHEMBL27505115 | 0.78 | AKR1C3 (0.97) | PTGS2PTGS1AKR1C3AKR1C2TSHR | |
| SCHEMBL11822617 | 0.77 | PTGS1 (0.79) | PTGS2PTGS1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, NR3C2, HRH1 | PTGS2 365/4885PTGS1 715/4885KDM4E 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.